---
document_datetime: 2026-01-19 17:04:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/effentora-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: effentora-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 14.8193162
conversion_datetime: 2026-01-20 20:37:28.189204
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Effentora

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                     | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Marketing Authorisation Transfer - H / | - Transfer of a marketing authorisation - | 05/12/2025                          | 09/01/2026                                  | SmPC, Labelling and              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/T/0000312945                         | Transfer of Marketing Authorisation from Teva B.V. to Phoenix Labs Unlimited Company                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000285167    | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC to add dysphagia to the list of adverse drug reactions (ADRs) with frequency not known, based on post-marketing data. The Package Leaflet is updated accordingly. | 16/10/2025 | 09/01/2026 | SmPC and PL | Update of section 4.8 of the SmPC to add dysphagia to the list of adverse drug reactions (ADRs) with frequency not known, based on post-marketing data. The Package Leaflet is updated accordingly. Amendments to the marketing authorisation. In view of the data submitted with the variation, amendments to Annex(es) I and IIIB are recommended. |
| Variation type IA_IN / EMA/VR/0000262256 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Accepted                                                                                                                                                                        | 11/04/2025 | 09/01/2026 | PL          | To update section 2 of the package leaflet to implement the wording agreed by the EMA following the CMDh position for PSUSA for fentanyl transdermal patches (PSUSA/00001370/202404).                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>